AstraZeneca: supply contract with Samsung
(CercleFinance.com) - Samsung Biologics, the biopharmaceutical division of the South Korean tech giant Samsung, announced on Monday evening that it has signed a big supply contract with AstraZeneca.
The long-term agreement provides for the supply to the Anglo-Swedish laboratory of the main assets for the manufacture of its products, as well as the transfer of certain medicinal products.
The contract will mean a payment of around 330.8 million dollars, which could be increased to 545.6 million dollars if necessary, the Korean bioproduction services company said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The long-term agreement provides for the supply to the Anglo-Swedish laboratory of the main assets for the manufacture of its products, as well as the transfer of certain medicinal products.
The contract will mean a payment of around 330.8 million dollars, which could be increased to 545.6 million dollars if necessary, the Korean bioproduction services company said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.